Allergic Conjunctivitis
📧 Sign up to get email alerts when something new happens for Allergic Conjunctivitis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-09-30FDA Approved: PATADAY TWICE A DAY RELIEF — Supplemental Application (Alcon Laboratories, Inc.)
The FDA approved a supplemental application for Pataday Twice a Day Relief (olopatadine hydrochloride) by Alcon Laboratories, expanding labe…
-
CLINICAL_TRIALS trial_result · 2020-09-14Clinical Trial Update: Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients [Phase 2]
Phase 2 trial assessing safety and efficacy of Bepotastine Besilate Ophthalmic Solution for seasonal allergic conjunctivitis completed with …
-
CLINICAL_TRIALS trial_result · 2020-09-14Clinical Trial Update: Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers [Phase 3]
A Phase 3 trial evaluating the safety of KetoNaph ophthalmic solution in healthy volunteers for allergic conjunctivitis has completed with r…
-
FDA approval · 2020-09-11FDA Approved: CETIRIZINE HYDROCHLORIDE — Original Application (Aurohealth LLC)
FDA approved the original generic application for cetirizine hydrochloride to be marketed by Aurohealth LLC.
-
CLINICAL_TRIALS trial_result · 2020-09-04Clinical Trial Update: Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis [Phase 2]
Phase 2 trial update for mapracorat ophthalmic formulation in subjects with allergic conjunctivitis has completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-08-06FDA Approved: OLOPATADINE HYDROCHLORIDE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application from Apotex Corp. for olopatadine hydrochloride (generic ophthalmic antihistamine). The approval cov…
-
FDA approval · 2020-07-15FDA Approved: OLOPATADINE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for olopatadine hydrochloride from Rising Pharma Holdings, Inc. The approval entails changes to …
-
FDA approval · 2020-07-15FDA Approved: OLOPATADINE HYDROCHLORIDE — Supplemental Application (Allwell Health Inc)
The FDA approved a supplemental application for the generic olopatadine hydrochloride from Allwell Health Inc under ANDA209995. The action u…
-
FDA approval · 2020-07-15FDA Approved: OLOPATADINE HYDROCHLORIDE — Supplemental Application (Harris Teeter)
FDA approved a supplemental application for olopatadine hydrochloride, a generic antihistamine eye drop, for Harris Teeter.
-
FDA approval · 2020-07-13FDA Approved: PATADAY ONCE DAILY RELIEF — Supplemental Application (Alcon Laboratories, Inc.)
The FDA approved a supplemental application to allow Pataday Once Daily Relief (olopatadine hydrochloride) for once-daily dosing in allergic…
-
FDA approval · 2020-07-02FDA Approved: OLOPATADINE HYDROCHLORIDE — Supplemental Application (Apotex Corp.)
The FDA approved a supplemental application for olopatadine hydrochloride filed by Apotex Corp., enabling changes to the approved product.
-
FDA approval · 2020-06-16FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (Rising Pharma Holdings, Inc.)
FDA approved an original application for olopatadine hydrochloride (generic), manufactured by Rising Pharma Holdings, Inc., as an approved g…
-
FDA label_change · 2020-06-09FDA Approved: LASTACAFT — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for LASTACAFT (alcaftadine) from Allergan, resulting in changes to the labeling.
-
FDA approval · 2020-06-01FDA Approved: KETOTIFEN FUMARATE — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved Unichem Pharmaceuticals (USA), Inc.'s original application for ketotifen fumarate as a generic antihistamine product. This mark…
-
FDA approval · 2020-05-20FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (Rugby Laboratories)
FDA approved the original ANDA for olopatadine hydrochloride ophthalmic solution (generic) from Rugby Laboratories.
-
FDA approval · 2020-05-08FDA Approved: AZELASTINE HYDROCHLORIDE — Original Application (Aurobindo Pharma Limited)
FDA approves the original application for azelastine hydrochloride from Aurobindo Pharma Limited.
-
FDA approval · 2020-05-07FDA Approved: OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application for olopatadine hydrochloride ophthalmic solution from Gland Pharma Limited, indicating an updated o…
-
CLINICAL_TRIALS trial_result · 2020-03-31Clinical Trial Update: The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer [Phase 4]
Phase 4 trial evaluating BEPREVE 1.5% on tear film osmolarity and lipid layer in allergic conjunctivitis completed with posted results.
-
FDA approval · 2020-03-03FDA Approved: CETIRIZINE HYDROCHLORIDE — Supplemental Application (Bionpharma Inc.)
The FDA approved a supplemental application for cetirizine hydrochloride by Bionpharma Inc., under ANDA078488, granting regulatory approval …
-
FDA approval · 2020-02-14FDA Approved: PATADAY ONCE DAILY RELIEF — Supplemental Application (Alcon Laboratories, Inc.)
The FDA approved a supplemental application for Pataday Once Daily Relief (olopatadine hydrochloride) from Alcon Laboratories, Inc.
-
FDA approval · 2020-02-14FDA Approved: PATADAY TWICE A DAY RELIEF — Supplemental Application (Alcon Laboratories, Inc.)
FDA approved a supplemental application for Pataday Twice A Day Relief containing olopatadine hydrochloride, expanding its labeling for alle…
-
FDA approval · 2020-02-05FDA Approved: ZERVIATE — Supplemental Application (Harrow Eye, LLC)
The FDA approved a supplemental application for ZERVIATE (cetirizine) submitted by Harrow Eye, LLC.
-
CLINICAL_TRIALS trial_result · 2020-01-29Clinical Trial Update: Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis [Phase 2]
Phase 2 trial evaluating PR013 topical ophthalmic drops versus vehicle for allergic conjunctivitis has completed.
-
FDA approval · 2020-01-28FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (Amneal Pharmaceuticals LLC)
FDA approves the original application for olopatadine hydrochloride, a generic antihistamine used to treat allergic conjunctivitis.
-
CLINICAL_TRIALS trial_result · 2019-08-06Clinical Trial Update: Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis [Phase 4]
Phase 4 clinical trial comparing Bepreve to Alrex in moderate to severe allergic conjunctivitis; completed with results posted in 2019.